- 34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms
- A Clinical Study to Evaluate the Safety and Performance of the Modular AAA Stent-Graft System
- A Large Surgical Registry for Abdominal Aortic Aneurysms (AAA)
- A MULTICENTER, OPEN LABEL, PROSPECTIVE, NON-RANDOMIZED STUDY OF INCRAFT™ IN SUBJECTS WITH ABDOMINAL AORTIC ANEURYSMS (INNOVATION)
- A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)
- A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
- A PROpensity Score Matching Analysis on ENDovascular vs Open Thoraco-Abdominal Aortic Aneurysm Repair (PRO-ENDO TAAA Study)
- A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
- A Retrospective, Observational Study to Collect Clinical Safety and Performance Data of POLYMAILLE® EXTRA THIN Vascular Prothesis
- A Retrospective, Observational, Multicenter, Study to Collect Clinical Safety and Performance Data on POLYMAILLE®C
- A Study of Remote Ischaemic Preconditioning in Patients With Atherosclerosis Undergoing Vascular Surgery
- A Study of the Safety of Targeted AAA Screening
- AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft
- AAA Rupture Risk Assessment in COVID-19 Pandemic
- Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks
- Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks – Netherlands
- Abdominal Aortic Aneurysm Screening Before Coronary Artery Bypass Surgery
- Abdominal Aortic Aneurysm Surgery and Thrombosis
- Abdominal Aortic Aneurysms and Pseudoexfoliation Syndrome
- ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.
- Acute Technical Outcomes of the Talent Abdominal Aortic Aneurysm (AAA) Stent-Graft Versus Cook Zenith Stent-Graft
- ACZ885 for the Treatment of Abdominal Aortic Aneurysm
- Advanced MRI in AAA
- ALTo endogrAft Italian Registry
- An Innovative Approach to Automated Carbon Dioxide Angiography During Endovascular Abdominal Aortic Aneurysm Repair
- Anatomical and Perioperative Predisposing Factor for LIMb Occlusion of IncrafT Infrarenal Endograft
- AneuFix – Prophylactic Sac Filling
- ANEUFIX for Endoleak Type II Repair
- ANEUFIX for Endoleaks Type II
- AneuRx Post Market Study in the Treatment of AAA
- Aneurysm Diameter and Surgical Outcome
- Aneurysma Hernia Study – Incidence of Incisional Hernias After Abdominal Aortic Aneurysm Repair
- Aortic Distensibility
- ARBITER-II: Aorfix™ Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels
- Arterial Stiffness, Blood Pressure and Cardiac Output Study
- Assessment of the Endovascular Aortic Aneurysm Repair’s (EVAR) Main Body Lateral Movement Impact on the Rate of Reintervention After AAA’s Treatment
- Biomarker Profiling in Abdominal Aortic Aneurysm Patients
- Biomarkers of Aneurysm Wall Strength
- BNP and Vascular Surgery
- Body Mass Index and Initial Presentations of Cardiovascular Diseases
- Carbon Dioxide Guided Angiography in Endovascular Abdominal Aortic Aneurysm Repair
- CCR2 AAA Pilot Study
- Central Blood Pressure and Variability Evaluation
- China Post-market Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INITIATION)
- Circulating microRNAs and Degenerative Abdominal Aorta Aneurysm
- Clinical Effectiveness of an Off-the-shelf Single REnal Scalloped sTent-graft for HOstile NEck Infrarenal Abdominal Aortic Aneurysm
- Clinical Study of Abdominal Aortic Aneurysm Exclusion (TALENT Abdominal)
- Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms
- Comparative Study of a Software With the Gold Standard
- Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)
- Comparison of Methods to Improve Abdominal Aortic Aneurysm (AAA) Screening Rates in the Primary Care Setting.
- Compassionate Use of the Incraft® AAA Stent Graft System
- Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm
- Complementary and Alternative Medicine Interventions in Targeting Pain
- Contrast Enhanced Ultrasound Endoleak Identification and Classification
- Contrast Enhanced Ultrasound, Endoleak Detection Following EVAR v1.3
- Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair
- Control Post Endovascular Treatment of Aortic Aneurisms Through Magnetic Resonance and Ultrasound (SAFEVAR)
- Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)
- CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial)
- Cross-sectional Study of Prevalence Rate of Abdominal Aortic Aneurysm in OSAHS Patients From BTCH
- Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair
- Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms
- Deep Learning Applied to Plain Abdominal Radiographic Surveillance After Endovascular Aneurysm Repair (EVAR) of Abdominal Aortic Aneurysm (AAA)
- Detecting Abdominal Aortic Aneurysms in First Degree Relatives (Adult Offsprings) to AAA Patients (DAAAD)
- Development of Novel Imaging Markers Predicting the Progression of Abdominal Aortic Aneurysm Using 3D Computed Tomography
- DOTATATE PETMRI AAA Study
- Dutch Randomised Endovascular Aneurysm Management (DREAM-) Trial
- DynaCT Imaging in EVAR: Comparing Clinical Benefit of DynaCT to Multidetector CT as the Current Gold Standard.
- DynaCT in Preoperative Imaging Before Insertion of Stentgraft
- E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms
- Effect of Pre-operative Exercise in Abdominal Aortic Aneurysms (AAA) Patients.
- Elective Abdominal Aortic Aneurism – Open Versus Endovascular Repair
- Elective Treatment Rates and Surgical Non-eligibility Among Men and Women With Intact Abdominal Aortic Aneurysms
- Emergency Department Ultrasound in Renal Colic
- Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms (AAA) Metabolic Activity
- Endovascular Aneurysm Repair (EVAR) Gate Study
- EndoVascular Aortic Repair With Sac Embolization for the Prevention of Type II Endoleaks (the EVAR-SE Study)
- Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
- Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts
- Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- Endovascular Treatment of Aorto-iliac Disease Using in Situ Fenestration
- Endurant Evo International Clinical Trial
- Endurant Evo US Clinical Trial
- EndurAnt Stent Graft System vs ExcluDer Endoprothesis: a Global, prospectiVe, rANdomized Clinical Trial in Sac rEgression (ADVANCE Study)
- Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques
- Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study
- European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms
- Evaluation of a New Imagingtechnologie for Thrombosis
- Evaluation of Effect of Angiotensin-converting Enzyme (ACE) Inhibitors on Small Aneurysm Growth Rate
- Evaluation of Predictors of Aortic Aneurysm Growth and Rupture
- EValuation of Systemic Atherothrombosis in Patients With ARTerial Disease of the Lower Limbs
- Evaluation of the Endovascular Repair for Aortic Aneurysm (EVAR) Program at LHSC
- Evaluation of the Impact of Prehabilitation on Recovery Following Open Surgery for Abdominal Aortic Aneurysm
- Evaluation of the Long Term Efficacy of Endovascular Treatment of Type 2 Endoleaks
- Evaluation of the Safety and Efficacy of the Multilayer Stent
- Female Aneurysm Screening STudy
- Fenestrated AAA Endovascular Graft Post-Approval Study
- First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA)
- Follow-up After Endovascular Repair of Abdominal Aortic Aneurysm
- Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair
- Global Fenestrated Anaconda Clinical sTudy
- Global Iliac Branch Study
- Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery
- GORE® EXCLUDER® Endoprosthesis French Mandatory Registry
- Haemostasis Management of Abdominal Aortic Procedures
- Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)
- Hellenic Registry of Ovation Alto™ Abdominal Stent Graft System
- Hemodynamic Changes After Aortic Aneurysm Treatment With Stent-Graft
- HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm
- Image Fusion of Preprocedural CTA With Real Time Fluoroscopy to Enhance EVAR Repair
- Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
- Impact of Intra- and Postoperative Continuous Infusion of Lidocaine on Analgesia in Vascular Anaesthesia
- Impact of Limb Remote Ischemic Preconditioning on Mortality and Quality of Life During Abdominal Aortic Aneurysm Repair
- Intact Abdominal Aortic Aneurysm Repair in Portugal
- Interest of a Post-operative Ultrasound With Systematic Use of Ultrasonic Contrast in the Follow-up of Aortic Endoprosthesis: Prospective Study at the University Hospital of Nice
- Intraoperative Assessment of Pulsatile Aneurysm Wall Motion During Endovascular Aneurysm Repair
- Intraoperative Perfusion Patterns of the Sigmoid Colon During Elective Open Abdominal Aortic Aneurysm Repair
- Italian Multicenter Database for Open Conversions After EVAR
- Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
- LIFE Study: Least Invasive Fast-Track EVAR
- Limb Remote Ischemic Preconditioning Reduces Heart and Lung Injury After Abdominal Aortic Aneurysm Repair
- Limiting AAA With Metformin (LIMIT) Trial
- Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial
- LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair
- Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- Magnetic Resonance Imaging To Predict Outcomes In Aortic Aneurysms
- Measurement of Maximum Diameter of Native Abdominal Aortic Aneurysm by Angio-CT
- Mechanism and Prevention of Remote Organ Injury Following Ruptured Aortic Aneurysm
- Metformin for Abdominal Aortic Aneurysm Growth Inhibition
- Metformin Therapy in Non-diabetic AAA Patients
- MuLtibranchEd Graft for OPen RepAir of ThoRacoabdominal Aneurysms
- NIH CCR2 AAA Study
- Non-invasive Monitoring of Endovascular Repair of Abdominal Aortic Aneurysm (VBA)
- Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey
- Optimizing CO2 Injection Technique for EVAR
- Overlay of 3D Scans on Live Fluoroscopy for Endovascular Procedures in the Hybrid OR
- Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial
- Performance and Safety of a Second Generation Antimicrobial Graft in Abdominal Position
- Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.
- Physician Modified Endovascular Grafts
- Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA)
- Point-of-care Ultrasound in Finland
- Post Implant Syndrome After EVAR and EVAS (INSPIRE Study)
- Post Implantation Syndrome and Administration on NSAIDs in Patients Undergoing EVAR for AAA
- Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
- Post-operative CT Follow up After Nellix Endoprosthesis Implantation
- Powerlink Bifurcated Stent Graft Long-Term Follow-up Study
- Preconditioning Shields Against Vascular Events in Surgery
- Preconditioning Shields Against Vascular Events in Surgery
- Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers
- Predicting Endoleaks Following Endovascular Aortic Aneurysm Repair Using 18F-Sodium Fluoride
- Predictors of AAA Expansion and/or Rupture
- Preferences for Open Vs. Endovascular Repair for Abdominal Aortic Aneurysm
- Preoperative Methylprednisolone in Endovascular Aortic Repair
- Prevalence and Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease
- Prevalence of Carotid Artery Stenosis and Abdominal Aortic Aneurysms in Brussels: a Population-based Screening Study.
- Prevention of Endoleaks Using Autologous Platelet Gel on Unruptured Abdominal Aortic Aneurysms
- Prevention of Incisional Hernia After Elective Open Abdominal Aortic Aneurysm (AAA) Repair
- Prevention of Type II Endoleaks During Endovascular Treatment of Abdominal Aortic Aneurysm: Endovascular Treatment Versus Combination With Coil Embolisation of the Aneurysmal Sac
- Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair
- Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft
- Prospective Aortic Biobank of POP-STAR
- Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark
- Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries
- Reduction of Myocardial Infarction by Preconditioning in Patients With Ruptured Abdominal Aortic Aneurysm
- Registry of Patients Treated by Preloaded Fenestrated Stent-graft Designs for Complex Endovascular Aortic Procedures (PLD.REG.)
- Relation betwEen Abdominal Aorta and Carotid Artery Responses to SymPathetic stimulatiON uSing duplEx Ultrasound
- Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access
- Risk Factors in the Initial Presentation of Specific Cardiovascular Disease Syndromes
- Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
- Safety and Efficacy of the SETA LATECBA Stent Graft for EVAR in Subjects With AAA
- Safety Study for the Treatment of Abdominal Aortic Aneurysms
- Screening Cardiovascular Patients for Aortic Aneurysms
- Screening Cardiovascular Patients for Aortic aNeurysms (SCAN)
- Screening for Abdominal Aortic Aneurysm and Abdominal Aortic Atherosclerosis by Hand-Held Ultrasonography
- Screening for Abdominal Aortic Aneurysm in 65 Year Old Males in Oslo
- Screening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound
- Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm
- Screening of Abdominal Aortic Aneurysms Among Male Patients With TIA Symptoms
- Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease
- Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care
- Serum Uric Acid Levels and Onset of Cardiovascular Diseases: a CALIBER Study
- Sex-specific Differences in AAA Complexity
- Sex-specific Differences in the Stress Response to Abdominal Aortic Aneurysm Repair
- Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study
- Sodium Fluoride Imaging of Abdominal Aortic Aneurysms
- South American Abdominal Stent Graft Trial
- START – Early Thrombocyte Administration to Patients With Ruptured Abdominal Aortic Aneurism
- Statin Use in Abdominal Aortic Aneurysm Repair
- Structured Exercise Programme and Abdominal Aortic Aneurysm Surgery
- Study of Abdominal Aortic Stent Grafts in the Treatment of Infrarenal Abdominal Aortic Aneurysms
- Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
- Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)
- Study of the Glycocalyx in Abdominal Aortic Aneurysm
- Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA’s and Mild Hypertension
- Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm
- Surviving Aneurysm Surgery: A Pilot Study on Exercise Training in Abdominal Aortic Aneurysm Patients
- Talent Aortic Cuff Stent Graft System Compassionate Use Registry
- Talent Converter Post-Approval Study
- Terumo Aortic Global Endovascular Registry
- The (PIVOTAL) Study
- The Altura Abdominal Aortic Aneurysm (AAA) Endograft Safety and Feasibility Study
- The Boston Scientific ENOVUS Trial
- The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
- The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.
- The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion
- The Inter and Intra Reliability of Cardiopulmonary Exercise Testing in Abdominal Aortic Aneurysm Patients
- The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms
- The Pivotal Study of the Aptus Endovascular AAA Repair System
- The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair
- The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study
- The Use of Carbon Dioxide as a Contrast Media for Performing Endovascular Procedures
- The Vascutek Custom Fenestrated Anaconda Post-Market Surveillance Study
- Tonometry and Duplex Ultrasound to Predict AAA Progression and CV Events in Aneurysm Patients (1-2-3 Trial)
- Tonometry(1) and Duplex Ultrasound(2) to Predict CV Events in to be Treated Patients With an AAA
- Totally Percutaneous Approach to Endovascular Treatment of Aortic Aneurysms (PEVAR-PRO)
- Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms
- TriVascular Canadian LIFE Study: Least Invasive Fast-Track EVAR (Endovascular Aneurysm Repair)
- TriVascular European Union (EU) Abdominal Stent Graft Trial
- TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair in Europe
- TriVascular Post-Market Registry
- Ultra-sound for AAA Screening in Smoking Israeli Arab Men
- Ultrasound Velocimetry in the Abdominal Aorta Before and After Endovascular Aneurysm Repair
- Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease
- Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair
- UVA Brain and Aortic Aneurysm Study
- Validation of Fenestrations Positioning by Numerical Simulation
- Vascutek Anaconda™ Abdominal Aortic Aneurysm (AAA) Post-Market Surveillance Registry
- Vasovist Endoleak Study
- ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for Abdominal Aortic Aneurysm
- White Blood Cell Counts and Onset of Cardiovascular Diseases: a CALIBER Study
- Zenith Low Profile AAA Endovascular Graft (ZLP) Clinical Study
- Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study
- Zenith(R) Low Profile AAA Endovascular Graft Clinical Study
- Zenith® AAA Endovascular Graft Clinical Study
- Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study
- Zenith® Low Profile AAA Endovascular Graft
- Zenith® Low Profile AAA Endovascular Graft
- Zenith® LP Abdominal Aortic Aneurysm (AAA) Post-Market Registry
- Zenith® p-Branch™: Single-Center Study
- Zenith® Spiral-Z® AAA Iliac Leg Graft Post-market Registry
Clinical Trials
- Children’s Healthy Living Community Randomized Trial
- Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism
- New Score for Pseudo- Acanthosis Nigricans
- Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia
- Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity
- Study of the Effect of Fractional co2 Laser Versus Q Switched:NdYAG Laser in the Treatment of Acanthosis Nigricans
- Sustainable-psycho-nutritional Intervention Program and Its Effects on Health Outcomes and the Environment
- The Effect of Laparoscopic Sleeve Gastrectomy on Insulin Secretion Pattern in Morbidly Obese Patients With Acanthosis Nigricans
- First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
- Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
- Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
- SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
- ACL-reconstruction vs ACL-reconstruction With EAT
- Blood Flow Restriction Following ACLR
- Comparing Adductor Canal Block and Adductor Canal Block-Local Infiltration Analgesia for Post-operative Pain Management
- Decreasing Knee Injury Risk Factors With Neuromuscular Training
- Dynamic ACL Brace: In Vivo Kinematics
- Feasibility of Electro Auricular Acupuncture for Analgesia After ACL Surgery: The Feasibility of Patient Blinding and Effects on Early Postoperative Pain
- Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery
- Laval University Rouge et or Post ACL Surgery Program Effectiveness
- LIVing Donor Allograft for Anterior Cruciate Ligament Reconstruction Study
- Mindfulness and ACL Surgery
- Post Operative Pain Management Through Adductor Canal Block With Bupivacaine for ACL Reconstruction
- Prospective Analysis of Introperative RegenLab PRP and Hyaluronic Acid in Patients With Knee ACL Tear
- RescueTEE for In-hospital Cardiac Arrest (ReTEECA Trial)
- Risk of Osteoarthritis of the Knee at Least 5 Years After ACL Reconstruction: Comparative Study Between an Isolated ACL Reconstruction and a Reconstruction Combining ACL and ALL
- Semitendinosus Graft as Meniscal Transplant
- The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction
- THE EFFECT OF RAMP LESION REPAIR ON RETURN TO SPORTS IN ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION
- Tibial Tunnel Widening in Anterior Cruciate Ligament (ACL) Reconstruction-Comparing Two Bioscrews
- Use of an Osteoconductive Scaffold in ACL-Reconstruction
- What is the Effect of Vision on Movement Control in Anterior Cruciate Ligament Reconstructed Patients 7 Months Post-surgery?
- What is the Influence of Visual-motor Reliance on Planned and Unplanned Change of Direction Biomechanics 7 Months Post Anterior Cruciate Ligament Reconstruction?
- A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
- A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
- A Prospective Study of Outcome After Therapy for Acromegaly
- A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
- A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
- A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
- A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
- A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
- ACRODAT Prospective Evaluation Study
- Acromegaly – Before and After Treatment
- Acromegaly & Sleep Apnoea
- Acromegaly Combination Treatment Study
- Acromegaly Treatment Quality of Life Study
- Acromegaly: Balance, Falls and Fracture Risk
- Acromegaly: Patient And Physician Perspectives
- Acute Application of Pegvisomant and Octreotide in Acromegaly
- An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
- An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
- An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
- Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation
- Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
- Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly
- Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
- Bone MicroArchitecture in Acromegaly
- Canadian Pegvisomant Compassionate Study In Acromegalic Patients
- Cardiac (CMRI) Assessment of Acromegaly
- Cardiovascular Outcome After Surgery or Somatostatin Analogues
- Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
- Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
- Clomiphene Citrate for Treatment of Acromegaly
- Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
- Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
- Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
- Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
- Developing a Simple Recognition System of Acromegaly
- Diet in the Management of Acromegaly
- Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
- Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
- Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
- Effects of Sandostatin LAR® in Acromegaly
- Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
- Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
- Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
- Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
- Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
- Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
- Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
- Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
- Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
- Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
- Epidemiology of Acromegaly in Denmark 1991-2010
- Estrogen Treatment in Acromegalic Women
- Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
- Fractionated Stereotactic Radiotherapy in Patients With Acromegaly
- Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance
- Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
- Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?
- Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
- Hypoproteic Diet in Acromegaly
- IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly
- Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
- Korean Regulatory Post Marketing Surveillance for Somavert
- Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
- Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
- Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
- Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
- Lanreotide Levels in Acromegaly
- Late Effects of Radiosurgery on Acromegaly Study
- Long Term Study With B2036-PEG
- Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
- Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
- Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients
- Non Interventional Post Marketing Programme in Acromegaly
- Non Interventional Study For Patients Treated With Somavert®
- Octreotide Efficacy and Safety in First-line Acromegalic Patients
- Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients
- One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
- Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
- Open Label Study of Octreotide Implant in Patients With Acromegaly
- Pasireotide LAR and Pegvisomant Study in Acromegaly
- Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
- Pegvisomant And Sandostatin LAR Combination Study
- Peri- and Post-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly During the First Year After Surgical Resection
- Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A.
- Phase II Study With ITF2984 in Acromegalic Patients
- Physiopathology of Sodium Retention in Acromegaly
- Prediction of Tumor Shrinkage in Acromegaly
- Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
- Predictive Factors Study
- Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
- Preoperative Octreotide Treatment of Acromegaly
- Programme of Acromegaly Screening in Patients With Associated Somatic Disorders
- Prospective Study on Changes in Acromegaly
- Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
- Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
- Rehabilitation Program in Patients With Acromegaly
- Reproducibility and Utility of OGTT in Acromegaly
- Rhinological Outcomes in Endonasal Pituitary Surgery
- Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
- Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
- Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
- Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
- SAGIT for Classification of Patients With Acromegaly in Clinical Practice
- Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
- Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients
- Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
- Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788
- Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
- Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
- Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects
- Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
- Somatuline Autogel: Acromegaly Self/Partner Injection Study
- Somatuline Predictive Factors in Acromegaly and NET
- Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
- Strict IGF-1 Control in Acromegaly
- Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
- Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
- Study in Polish Acromegalic Patients Treated With Somatuline Autogel
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing’s Disease or Acromegaly
- Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
- Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
- Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
- Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
- Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
- Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
- Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
- Surgical Versus Medical Treatment of Acromegaly
- The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
- The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
- The Observational Study of Growth Hormone-secreting Pituitary Tumors
- The TMS Treatment for Postoperative Headache in GH Tumor
- The Treatment and Natural History of Acromegaly
- Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
- Tissue Biomarker for Pegvisomant Action
- Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
- Treatment Patterns and Treatment Outcomes for Acromegaly
- Ultrasound Guided Octreotide LAR Injection in Acromegaly
- Validation Study of the SAGIT® Instrument in Acromegaly
- Vitamin D Metabolism in Patients With Endocrine Disorders
- Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment
- Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
- Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip
- Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis
- Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy
- A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent
- Acclimatization Mechanisms During Ascent to 7500m
- Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD
- Alternative Treatments in Acute Mountain Sickness
- Altitude Sickness Prevention and Efficacy of Comparative Treatments
- Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy
- AZ, MZ, and the Pulmonary System Response to Hypoxia
- Breathing Training to Improve Human Performance at High Altitude
- Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness
- Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely
- Chronic Mountain Sickness, Systemic Vascular Function
- Colorado-Oregon Altitude Study
- Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness
- Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness
- Decompression Tables for Diving at Altitude
- Drug Combination on Exercise Performance at High Altitude
- Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years
- Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude
- Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude
- Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude
- Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.
- Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude
- Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude
- Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude
- Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude
- Effect of Altitude on Iron Absorption in Iron Depleted Women
- Effect of Isocaloric Ketogenic Diet on Physical Performance at High Altitude
- Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort
- Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.
- Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness
- Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude
- HIGH Altitude CArdiovascular REsearch Latin America Population Study
- Inhaled Budesonide and Acute Mountain Sickness
- Inhaled Budesonide for Altitude Illness Prevention
- Iron Status and Cardiopulmonary Physiology
- Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude
- Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide
- Oxidative Stress in Hypobaric Hypoxia
- Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance
- Prevention of Acute Mountain Sickness by Intermittent Hypoxia
- Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)
- Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness
- Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
- Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
- Safety Evaluation of Aminophylline and Methazolamide
- Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages
- Sickness Evaluation at Altitude With Acetazolamide at Relative Doses
- Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)
- Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)
- Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness
- Study of the Effects of Iron Levels on the Lungs at High Altitude
- The Effects of Intermittent Hypoxia on Acute Hypoxic Injury
- The Pre-acclimatization Augmented Extreme Altitude Expedition
- The Psychophysiological Effect of Simulated and Terrestrial Altitude
- Three New Ideas to Protect Special Forces From the Stress of High Altitude
- Training in Hypoxia to Prevent Acute Mountain Sickness
- AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- AML Therapy With Irradiated Allogeneic Cells
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
- Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
- Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)
- Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy
- Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
- Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
- Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
- CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
- Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
- Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
- Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
- Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
- Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study.
- Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
- Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
- S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
- Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia
- Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
- Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
- Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
- Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
- Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
- A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old
- A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)
- A Safety Study of SGN-CD33A in AML Patients
- A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
- A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
- A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- AIDA 2000 Guidelines
- All-trans Retinoic Acid, and Arsenic +/- Idarubicin
- An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
- AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
- ASCT for Relapsed APL After Molecular Remission
- Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
- Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
- Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
- Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
- Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
- Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
- Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
- Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
- Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
- Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML
- Connect® MDS/AML Disease Registry
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
- Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
- Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
- Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly
- Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL.
- FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
- Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
- French Registry of First-line Treatment of Acute Promyelocytic Leukemia
- Frontline Oral Arsenic Trioxide for APL
- Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
- Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
- GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
- GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
- Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia
- MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
- New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
- Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
- Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
- Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
- Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
- Proteasome Inhibition in Acute Promyelocytic Leukemia
- PXD101 in Treating Patients With Acute Myeloid Leukemia
- Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission
- Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL
- Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
- Red Cell Transfusion Goals in Patients With Acute Leukemias
- Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
- Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
- Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
- Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
- Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
- Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
- The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
- Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant
- Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia
- Total Marrow Irradiation for Refractory Acute Leukemia
- Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
- Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
- Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
- Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
- Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
- Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
- Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
- Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
- Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
- Vorinostat in Treating Patients With Acute Myeloid Leukemia
- A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
- A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
- A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
- Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
- Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
- ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
- An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
- APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
- Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
- Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
- Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
- Circulating Tumor DNA in Patients at High Risk for Lung Cancer
- Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
- Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
- Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
- Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma
- Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis
- Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
- Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy
- ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
- Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
- Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
- Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
- Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS
- Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology
- Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
- Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
- Icotinib for Completed Resected IB NSCLC With EGFR Mutation
- Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
- Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
- LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
- Lung Cancer Mutation Consortium Protocol
- NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
- P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC
- Phase 1/2 Study of CISH Inactivated TILs in the Treatment of NSCLC
- Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors
- Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
- Photodynamic Therapy in Treating Patients With Lung Cancer
- Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
- Prognostic Value of Lung Cancer MicroAnatomy in 3D
- Prospective Radiological Study of HRCT to Predict Pathological Noninvasiveness in NSCLC
- QUILT-3.017: Study of NEO-201 in Solid Tumors
- Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
- S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
- S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
- S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
- Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
- Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
- Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
- Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
- Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
- Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
- Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer
- Telomere Biology in Early Adenocarcinoma of the Lung
- The Detection of EGFR Mutations in Liquid Based Cytology Samples
- The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
- The Tracking Molecular Evolution for NSCLC (T-MENC) Study
- Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
- Therapeutic ResistAnce and Clonal Evolution of ICIs
- To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
- Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
- Vaccine Treatment for Advanced Non-Small Cell Lung Cancer